

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))					Docket No. KPO-LTT-P1/LTT-85/	
In Re Application Of: Ishihara, T.						
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.	
10/550,990 ✓	N/A	to be assigned	44702	1615	8274	
Title: Intravenous nanoparticles for targeting drug delivery and substaisted drug release						
Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450						
37 CFR 1.97(b)						
1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.						
37 CFR 1.97(c)						
2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:						
<input type="checkbox"/> the statement specified in 37 CFR 1.97(e);						
OR						
<input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).						

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
KPO-LTT-P1/LTT-85/

In Re Application of: **Ishihara, T.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/550,990	N/A	to be assigned	44702	1615	8274

Title: **Intravenous nanoparticles for targeting drug delivery and substandard drug release**

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 50-3195
as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa
_____ (Date)
_____ Signature
_____ Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on
_____ March 28, 2006 (Date)
_____ Signature of Person Mailing Correspondence
_____ Manette Dennis
_____ Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Signature

Dated: **March 28, 2006**

Manette Dennis (Reg. No. 30,623)
Ostrager Chong Flaherty & Broitman P.C.
250 Park Avenue, Suite 825
New York, New York 10177-0899

cc: **Dr. Osamu Kusama**

Application Serial No. 10/550,990
Information Disclosure Statement – Additional Sheet

Sheet 2 of 3

Application Serial No. 10/550,990

Applicants: ISHIHARA, T

entitled: INTRAVENOUS NANOPARTICLES FOR TARGETING DRUG DELIVERY
AND SUSTAINED DRUG RELEASE

EP 1 398 025 A is the European regional application corresponding to WO 02/096396 A1. WO 02/096396 A1 is listed on the International Search Report for PCT/JP2004/003246 and was published on Dec. 5, 2002. EP 1 398 025 A1 is provided as an English equivalent to WO 02/096396 A1.

Japanese National Publication No. Hei 10-511957 is listed on page 1 of the application as filed. It is the Japanese National Phase application for International Application No. PCT/US96/00476. International Application No. PCT/US96/00476 was published as WO 96/20698, which is enclosed as a translation of Japanese National Publication No. Hei 10-511957.

[illegible]

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁶
		Country Code ³	Number⁴	Kind Code ⁵ (if known)			
	d	EP	1 002 529	A1	05-24-2000	Takeda Chemical Industries	whole document
	e	EP	1 398 025	A1	03-17 -2004	LTT Bio-Pharma Co., Ltd.	whole document
lish	f	JF	8-217691		08-27-1996	Takeda Chem Ind Ltd	whole document ✓
tations	g	JP	H01-10-644957		11-17-1998	Univ Michigan	whole document ✓
ed	h	JP	2003-242106		12-03-2003	Matsushita KK	whole document ✓

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.D./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/550,990	
			Filing Date	N/A	
			First Named Inventor	Ishihara, T.	
			Art Unit	1615	
			Examiner Name	to be assigned	
Sheet	2	of	3	Attorney Docket Number	KPO-LTT-P1/LLT-85/US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	i	ALLEMANN, ERIC et al., PEG-coated Poly(lactic acid) Nanoparticles for the Delivery of Hexadecalfuoro Zinc Phthalocyanine to EMT-6 Mouse Mammary Tumours, J. Pharm. Pharmacol., 1995, 382-387, Volume 47.	

Examiner Signature	/Paul Dickinson/	Date Considered	12/13/2007
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.D./